Must AI methods be pre-specified in clinical trials?

Yes. AI analytical methods should be described in the statistical analysis plan before unblinding. Post-hoc AI analysis is considered exploratory and cannot serve as the primary basis for efficacy claims.

Does 21 CFR Part 11 apply to AI in trials?

Yes. AI systems processing clinical trial data must comply with Part 11 requirements for electronic records, including audit trails, access controls, and ALCOA data integrity principles.

Can AI select patients for clinical trials?

AI can assist with patient identification and enrichment, but selection criteria must be validated, transparently documented, and assessed for bias that could limit generalizability of results.

How should AI be documented in trial submissions?

AI methodology should be described in detail, including algorithm design, training data, validation approach, and the relationship between AI-derived insights and traditional evidence supporting the application.

What are concerns about AI in adaptive trial design?

AI-driven adaptations must follow existing adaptive design guidance. Adaptation rules must be pre-specified, and the statistical properties of the adapted design must be well-characterized to maintain trial validity.

Quick answer

AI in clinical trials must comply with existing trial regulations (ICH GCP, 21 CFR Part 11) while following emerging guidance requiring pre-specification of AI methods and transparent documentation of AI-assisted decisions.

Updated June 2026 · MmowW AI Compliance

AI in Clinical Trials: Regulatory Compliance for AI-Driven Trial Design and Analysis (2026)

AI in Clinical Trials

AI is reshaping clinical trials from design through analysis. Applications include adaptive trial design, patient identification and recruitment, site selection, real-world data integration, endpoint prediction, and safety signal detection. Each application carries regulatory considerations rooted in existing clinical trial frameworks.

Regulatory Framework

Clinical trials remain governed by ICH Good Clinical Practice (GCP), regional regulations (21 CFR Parts 50, 56, 312 in the US), and the EU Clinical Trials Regulation. AI tools used within trials must comply with these existing frameworks while meeting emerging AI-specific expectations.

AI Application	Regulatory Concern	Compliance Approach
Adaptive trial design	Statistical validity	Pre-specify adaptation rules; follow adaptive design guidance
Patient recruitment	Selection bias, privacy	Document AI criteria; validate against manual screening
Endpoint analysis	Data dredging concerns	Pre-specify AI methods in SAP
Safety monitoring	Signal detection reliability	Validate AI tools; maintain human review
Real-world data	Data quality and relevance	Document data sources and curation

Pre-Specification Requirements

A foundational regulatory principle is that analytical methods should be pre-specified before data are examined. When AI is used for trial data analysis, the methodology must be described in the statistical analysis plan (SAP) before unblinding. Post-hoc AI analysis may be exploratory but cannot serve as the primary basis for efficacy claims.

21 CFR Part 11 and Data Integrity

AI systems processing clinical trial data must comply with 21 CFR Part 11 requirements for electronic records and signatures, including audit trails, access controls, and data integrity. AI-generated records must be attributable, legible, contemporaneous, original, and accurate (ALCOA principles).

AI in Patient Selection

AI-driven patient enrichment strategies must be validated and their criteria transparently documented. Regulators are concerned about selection bias that could limit the generalizability of trial results. The protocol should clearly describe AI selection criteria and their rationale.

Decentralized Trials and AI

Decentralized clinical trials increasingly use AI for remote monitoring, digital biomarker collection, and patient engagement. These applications must comply with GCP requirements for subject protection while addressing data privacy and security in remote settings.

Practical Compliance Steps

Pre-specify all AI analytical methods in the statistical analysis plan
Validate AI tools used in trial operations against established methods
Ensure 21 CFR Part 11 compliance for AI-generated records
Document AI patient selection criteria and validate for bias
Maintain human oversight of AI-assisted safety monitoring
Address data privacy for AI processing patient data
Include AI methodology descriptions in regulatory submissions

Check your AI compliance readiness — free.

Take the Readiness Check 3 minutes · 10 questions · no signup required

This article is for informational purposes only and does not constitute legal advice. Regulatory requirements change frequently — verify current rules with official sources. Built by Sawai Gyoseishoshi Office, Hiroshima, Japan.